Log in with your email address username.


[Correspondence] Essential medicines for universal health coverage

In the Lancet Commission on Essential Medicines Policies by Veronika Wirtz and colleagues (Jan 28, p 403),1 substandard, spurious, falsely labelled, falsified, and counterfeit medicines are discussed. The extent of the problem is mainly pervasive in low-income and middle-income countries,2,3 but we hope to share a recent unprecedented event involving a counterfeit drug in Japan, a country that was thought to have sophisticated medicine quality and safety.